MIRROR IMAGE
DEAD

Serial Number

76313158

Owner

NOXXON Pharma

Attorney

LISA V MUELLER

Filing Date

Sep 17, 2001

Add to watchlist:

No watchlists yet
View on USPTO

MIRROR IMAGE Trademark

Serial Number: 76313158 • Registration: 2694903

MIRROR IMAGE is a trademark filed by NOXXON Pharma on September 17, 2001. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

NOXXON Pharma

Gustav-Meyer Allee 25
13355 Berlin , DE

Entity Type: 99

Trademark Details

Filing Date

September 17, 2001

Registration Date

March 11, 2003

Published for Opposition

December 17, 2002

Cancellation Date

October 17, 2009

Goods & Services

Scientific, electronic, photographic, optical, measuring, signaling and controlling apparatus and instruments, namely, analytical devices comprising polynucleotides, polypeptides or polynucleotides and polypeptides as detection means; magnetic data medium, namely tapes, discs, diskettes and CDs, preferably containing sequence data on polynucleotides, polypeptides or polynucleotides and polypeptides; computers; computer software for designing target specific polynucleotides and polypeptides and software for use in the field of synthesis of nucleic acids and peptides, proteins and control of synthesis machines

Pharmaceutical and veterinary products, namely, preparations for sanitation, slimming, appetite suppressants, pharmaceuticals for acidosis therapeutics, analeptic and antihypoxaemics; analgetics and antirheumatic drugs, pharmaceuticals functioning as antihelmintics, antiallergics, antianemia drugs, antiarrhythmics, antibiotics and antiinfectives, antidementics, nootropics, antidiabetics, antidotes for the treatment of poisoning, antiemetics and antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolyrics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, pharmaceuticals functioning as antiparasitics, antiphlogistics, antitussives, expectorants for use in atherosclerosis, balneotherapeutics and pharmaceuticals for thermal therapy, pharmaceuticals functioning as beta receptor blocking agents, pharmaceuticals for calcium channel blocking and inhibiting of the renin angiotensin-system, pharmaceuticals functioning as broncholytics and antiasthmetics cholagoguegics and for use in biliary tract therapeutics; pharmaceuticals functioning as cholinergics, corticoids, dermatics; all purpose disinfectants and antiseptics; pharmaceuticals functioning as dietetic agents and in alimentary therapeutics; diagnostic preparations functioning as diuretics, as agents for favoring blood flow, as withdrawal agents, as fibrinolytics, to treat gout, the flu and catarrhal fever; pharmaceuticals for the treatment of gynecological illnesses, namely, menstrual cramps, hemorrhoids, hepatitis; pharmaceuticals functioning as hypnotics and sedatives; pharmaceuticals to treat cardiac ailments; pharmaceuticals for use in caries and parodontosis; dental preparations, namely, dental abrasives; laxatives, pharmaceuticals functioning as antilipaemics, local anaesthetics, neural therapeutics, gastro-intestinal preparations, pharmaceuticals to treat migraines; pharmaceutical preparations for use in mouth and pharyngeal therapeutics; pharmaceuticals for use as muscle relaxants; pharmaceuticals for the treatment of addiction to narcotics; pharmaceuticals for use in neuropathology; ophthalmic pharmaceuticals for treating blindness, conjunctivitis, cataract, glaucoma, retinal detachment, stye, chalazion, dacryoadenitis, corneal clouding, keratitis, gasserian ganglionitis, vitreous opacity, amaurosis, retinopathy, central retinal artery occlusion, retinoblastoma, melanoma, optic neuritis, optic nerve atrophy; pharmaceuticals for use osteoporosis and calcium metabolism modification; pharmaceuticals for the treatment of Parkinson's Disease and disturbances of the extrapyramidal system; pharmaceuticals for psychotropic, rhinologic and sinositic purposes; pharmaceuticals functioning as roborants and tonics; pharmaceuticals for use in thyroidal therapeutics; pharmaceuticals functioning as spasmolytics and inhibitors of thrombocyte aggregation; pharmaceuticals for the treatment of tuberculosis; pharmaceuticals functioning as alternants, urologics and venous agents; vitamins; pharmaceuticals for use as cytostatics and antineoplastic agents; homeopathic remedies, and medical plastics, namely sanitary preparations

Chemical products, namely polynucleotides, preferably containing at least one L-nucleotide, polypeptides, preferably containing at least one D-amino acid, compounds consisting in whole or in part of nucleic acids or derivatives thereof, for industrial, scientific, agricultural, gardening and forestry purposes; D- and L- nucleotides for use in manufacturing pharmaceuticals; L- and D- amino acids for use in manufacturing pharmaceuticals

Research and product development services for others in the filed of veterinary medicine, human medicine and agriculture; research and product development for others in the science and medical industries; computer services, namely, designing programs for others in data processing; chemistry consultation; biology consultation; biochemistry consultation; biotechnology consultation; gene technologies consultation; molecular biology consultation; pharmaceutical advice; medical services, veterinary services

Filing History

CANCELLED SEC. 8 (6-YR)
Oct 17, 2009 C8..
CASE FILE IN TICRS
May 28, 2008 CFIT
REVIEW OF CORRESPONDENCE COMPLETE
Oct 24, 2007 CORV
PAPER RECEIVED
Oct 18, 2007 MAIL
REVIEW OF CORRESPONDENCE COMPLETE
Sep 10, 2006 CORV
PAPER RECEIVED
Jun 18, 2004 MAIL
REGISTERED-PRINCIPAL REGISTER
Mar 11, 2003 R.PR
PUBLISHED FOR OPPOSITION
Dec 17, 2002 PUBO
NOTICE OF PUBLICATION
Nov 27, 2002 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 16, 2002 CNSA
EXAMINERS AMENDMENT MAILED
Sep 9, 2002 CNEA
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 28, 2002 CRFA
PAPER RECEIVED
May 28, 2002 MAIL
Sec. 1(B) CLAIM DELETED
May 22, 2002 1.BD
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 22, 2002 CRFA
NON-FINAL ACTION MAILED
Nov 26, 2001 CNRT
ASSIGNED TO EXAMINER
Nov 16, 2001 DOCK